Zacks Investment ResearchThu, 23 Apr 2026 18:16:08 GMTAltimmune Catalysts: 2026 Data Readouts and Financing RisksALT+1.64%
Zacks Investment ResearchThu, 23 Apr 2026 18:10:59 GMTALT Stock: What Pemvidutide Means for MASH, AUD and ALDALT+1.64%
Zacks Investment ResearchThu, 23 Apr 2026 18:06:09 GMTIs Altimmune a Buy Before Phase III MASH Starts in 2026?ALT+1.64%
Zacks Investment ResearchThu, 26 Mar 2026 16:06:10 GMTALT Stock and the 2026 MASH Race: Dual Agonists vs. New MechanismsALT+1.64%
Zacks Investment ResearchThu, 26 Mar 2026 14:43:07 GMTAltimmune Stock: Neutral Outlook With Big 2026 CatalystsALT+1.64%
Zacks Investment ResearchThu, 26 Mar 2026 14:26:11 GMTALT Pemvidutide Explained: What Makes It Different in MASHALT+1.64%
Seeking AlphaThu, 05 Mar 2026 19:15:56 GMTAltimmune, Inc. (ALT) Q4 2025 Earnings Call TranscriptALT+1.64%